EDAP TMS reported worldwide revenue of EUR 13.1 million (USD 14.4 million) for the third quarter of 2024, marking an 11.6% increase over the same period in 2023. The core HIFU business demonstrated substantial growth, with worldwide HIFU revenue reaching EUR 4.5 million (USD 4.9 million), a 48.2% increase year-over-year.
U.S. Focal One HIFU procedures experienced a 34% year-over-year growth, indicating increasing adoption of the company's robotic HIFU technology. Additionally, the Centers for Medicare & Medicaid Services (CMS) announced a 5.4% increase in the Medicare Hospital Outpatient Focal One HIFU procedure payment for 2025, which is a positive development for future revenue.
The company also announced an AI collaboration with Avenda Health for its Focal One Robotic HIFU platform. This collaboration aims to further enhance the capabilities and precision of the Focal One system, supporting its leadership in focal therapy for prostate cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.